Unlock stock picks and a broker-level newsfeed that powers Wall Street.
ASX Penny Stocks To Watch In March 2025

In This Article:

The Australian market has shown a mixed performance, with the ASX200 closing slightly up by 0.07% at 7,942 points, driven by gains in the IT and Health Care sectors. Investing in penny stocks—though an outdated term—still holds relevance today as these typically smaller or newer companies can offer unique growth opportunities when supported by solid financial health. In light of current market conditions, we will explore three penny stocks that stand out for their potential to combine affordability with resilience.

Top 10 Penny Stocks In Australia

Name

Share Price

Market Cap

Financial Health Rating

CTI Logistics (ASX:CLX)

A$1.675

A$130.67M

★★★★☆☆

Accent Group (ASX:AX1)

A$1.805

A$1.02B

★★★★☆☆

EZZ Life Science Holdings (ASX:EZZ)

A$1.565

A$73.83M

★★★★★★

IVE Group (ASX:IGL)

A$2.44

A$377.93M

★★★★★☆

GTN (ASX:GTN)

A$0.655

A$128.63M

★★★★★★

West African Resources (ASX:WAF)

A$2.20

A$2.51B

★★★★★★

Bisalloy Steel Group (ASX:BIS)

A$3.12

A$148.04M

★★★★★★

Regal Partners (ASX:RPL)

A$2.54

A$851.91M

★★★★★★

NRW Holdings (ASX:NWH)

A$2.80

A$1.28B

★★★★★☆

LaserBond (ASX:LBL)

A$0.395

A$46.35M

★★★★★★

Click here to see the full list of 979 stocks from our ASX Penny Stocks screener.

Let's uncover some gems from our specialized screener.

EMVision Medical Devices

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: EMVision Medical Devices Ltd focuses on the research, development, and commercialization of neurodiagnostic technology for stroke diagnosis and monitoring in Australia, with a market cap of A$169.75 million.

Operations: The company's revenue segment is derived entirely from the research and development of medical device technology, amounting to A$8.06 million.

Market Cap: A$169.75M

EMVision Medical Devices, with a market cap of A$169.75 million, is pre-revenue and focuses on neurodiagnostic technology. Despite being unprofitable, it has reduced losses over the past five years by 3.5% annually. The company has sufficient short-term assets (A$17.3M) to cover both its short-term (A$2M) and long-term liabilities (A$2.4M), and more cash than debt, indicating financial stability for now. Recent inclusion in the S&P/ASX All Ordinaries Index may boost visibility among investors, although its net loss increased significantly to A$3.57 million for the half-year ended December 2024 compared to the previous year.

ASX:EMV Debt to Equity History and Analysis as at Mar 2025
ASX:EMV Debt to Equity History and Analysis as at Mar 2025

MyState

Simply Wall St Financial Health Rating: ★★★★★☆